Publish in this journal
Journal Information
Vol. 71. Issue 9.
Pages 770 (September 2018)
Share
Share
Download PDF
More article options
Vol. 71. Issue 9.
Pages 770 (September 2018)
Letter to the Editor
DOI: 10.1016/j.rec.2018.03.021
Full text access
Phenotype-modifying Factors in Hypertrophic Cardiomyopathy
Factores modificadores del fenotipo en la miocardiopatía hipertrófica
Visits
...
Javier Limeres Freire
Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Related content
Rev Esp Cardiol. 2018;71:146-5410.1016/j.rec.2017.06.002
Inmaculada Pérez-Sánchez, Antonio José Romero-Puche, Esperanza García-Molina Sáez, María Sabater-Molina, José María López-Ayala, Carmen Muñoz-Esparza, David López-Cuenca, Gonzalo de la Morena, Francisco José Castro-García, Juan Ramón Gimeno-Blanes
Rev Esp Cardiol. 2018;71:770-110.1016/j.rec.2018.04.023
Inmaculada Pérez-Sánchez, María Sabater-Molina, Carmen Muñoz-Esparza, Juan Ramón Gimeno-Blanes
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

I read with great interest the article by Pérez-Sánchez et al.,1 published in Revista Española de Cardiología. The article reports that the phenotypic expression of hypertrophic cardiomyopathy (HCM) is not exclusively due to the necessary genetic factor; that is, the presence of a pathogenic mutation. Other factors also play a part, such as nongenetic environmental factors, as has been seen in previous studies performed in monozygotic twins with HCM.2 However, as the article indicates, the differences observed in the within-family phenotypic expression of HCM should not necessarily be considered a consequence of environmental factors.

Although patients who are members of the same family or who share haplotypes show less genetic variability, as occurs in the founder effect,3 we now know that these patients are not free from allelic differences in regulating genes, protective genes, or phenotype facilitators. In fact, despite the discordant results seen in various published series, certain polymorphisms from the renin-angiotensin-aldosterone system have been related to facilitating left ventricular hypertrophy in HCM patients. Nonetheless, attempts to extrapolate these findings to other populations or other mutations have not yielded concordant results.4 This disparity may indicate that the pathogenic mechanisms differ for each type of mutation, even mutations within the same gene, which would make interpretation of the variations due to genetic causes even more difficult. Our understanding of phenotypic heterogeneity becomes complex when we take into account epigenetic mechanisms that can contribute to the manifestation of the disease. In this regard, the authors mention the limitation posed by the inability to evaluate the presence of double mutations. However, the genetic factors influencing phenotypic expression of HCM should not be restricted to the presence of pathogenic mutations. In fact, it is expected that future studies investigating the complete genomic, epigenomic, and transcriptomic associations will be of help to understand the within-family variability due to genetic factors.

The authors conclude that the disease is diagnosed earlier in males with normal blood pressure who practice sports, and that the patient's sex, hypertension, and degree of physical activity do not show a significant association with the severity of left ventricular dysfunction in patients with the causal mutations of HCM. However, the results obtained may not be applicable to patients with HCM due to mutations in other genes or even those with other mutations within the same gene.

HCM can be considered a complex disease, as are all familial heart diseases, an area where the development of management protocols is essential.5,6 Studies such as that by Pérez-Sánchez et al.1 will help us to better understand HCM, abolish the myths about factors that influencing this disease, and offer new perspectives for related research.

.

References
[1]
I. Pérez-Sánchez, A.J. Romero-Puche, E. García-Molina Sáez, et al.
factors influencing the phenotypic expression of hypertrophic cardiomyopathy in genetic carriers.
Rev Esp Cardiol., 71 (2018), pp. 146-154
[2]
P. Palka, A. Lange, D.J. Burstow.
Different presentation of hypertrophic cardiomyopathy in monozygotic twins.
Heart., 89 (2003), pp. 751
[3]
Y. Dingge, C.S. Pak, K.S. David, Z. Lu, L.L. Yu, Y. Wanling.
HaploShare: identification of extended haplotypes shared by cases and evaluation against controls.
Genome Biol., 16 (2015), pp. 92
[4]
I.C. Kolder, M. Michels, I. Christiaans, et al.
The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy.
Eur J Hum Genet., 20 (2012), pp. 1071-1077
[5]
R. Barriales-Villa, J.R. Gimeno-Blanes, E. Zorio-Grima, et al.
Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms.
Rev Esp Cardiol., 69 (2016), pp. 300-309
[6]
F. Segura-Villalobos, A.I. Hernández-Guerra, F. Wanguemert-Pérez, et al.
Hypertrophic cardiomyopathy without ventricular hypertrophy: usefulness of genetic and pathological study in preventing sudden death.
Rev Esp Cardiol., 70 (2017), pp. 604-606
Copyright © 2018. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?